<unk>  can be prevented by the chickenpox vaccine if the vaccine is administered before the individual gets chickenpox. If primary infection has already occurred, there are<unk>  vaccines that reduce the risk of developing<unk>  or developing severe<unk>  if the disease occurs. They include a live attenuated virus vaccine, Zostavax, and an adjuvanted subunit vaccine, Shingrix. A review by Cochrane concluded that Zostavax was useful for preventing<unk>  for at least three years. This equates to about 50% relative risk reduction. The vaccine reduced rates of persistent, severe pain after<unk>  by 66% in people who contracted<unk>  despite vaccination. Vaccine efficacy was maintained through four years of follow up. It has been recommended that people with primary or acquired immunodeficiency should not receive the live vaccine. Two doses of Shingrix are recommended, which provide about 90% protection at 3.5 years. As of 2016, it had been studied only in people with an intact immune system. It appears to also be effective in the very old. In the UK,<unk>  vaccination is offered by the National Health Service (NHS) to all people in their 70s. Zostavax is the usual vaccine, but Shingrix vaccine is recommended if Zostavax is unsuitable, for example for those with immune system issues. Vaccination is not available to people over 80 as "it seems to be less effective in this age group". By August 2017, just under half of eligible 70–78 year olds had been vaccinated. About 3% of those eligible by age have conditions that suppress their immune system, and should not receive Zostavax. There had been 1,104 adverse reaction reports by April 2018. In the US, it is recommended that healthy adults 50 years and older receive two doses of Shingrix, two to six months apart.
Shingles
Insect bites and stings
Sealpox
Angina
Farmyard pox
Herpes simplex
Streptococcal intertrigo
Sciatica